Effect of nintedanib on lung function in patients with systemic sclerosis ‐associated interstitial lung disease: further analyses of a randomized, double‐blind, placebo‐controlled trial

AbstractFollowing the publication of further analyses of the effects of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in the SENSCIS trial (1), Dr Bredemeier queried whether the occurrence of gastrointestinal adverse events in subjects treated with nintedanib may have reduced the effectiveness of masking and so introduced bias (2).

Source: Arthritis and Rheumatology - June 9, 2021 Category: Rheumatology Authors: Toby M Maher, Maureen D Mayes, Christian Stock, Margarida Alves Tags: REPLY Source Type: research